AR016001A1 - Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente - Google Patents

Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente

Info

Publication number
AR016001A1
AR016001A1 ARP980105513A ARP980105513A AR016001A1 AR 016001 A1 AR016001 A1 AR 016001A1 AR P980105513 A ARP980105513 A AR P980105513A AR P980105513 A ARP980105513 A AR P980105513A AR 016001 A1 AR016001 A1 AR 016001A1
Authority
AR
Argentina
Prior art keywords
patient
integer
manufacture
amine polymers
alifatic
Prior art date
Application number
ARP980105513A
Other languages
English (en)
Spanish (es)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR016001A1 publication Critical patent/AR016001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP980105513A 1997-11-05 1998-11-03 Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente AR016001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/964,956 US5985938A (en) 1997-11-05 1997-11-05 Method for reducing oxalate

Publications (1)

Publication Number Publication Date
AR016001A1 true AR016001A1 (es) 2001-05-30

Family

ID=25509224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105513A AR016001A1 (es) 1997-11-05 1998-11-03 Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente

Country Status (10)

Country Link
US (3) US5985938A (enExample)
EP (2) EP1044008B1 (enExample)
JP (1) JP4452402B2 (enExample)
AR (1) AR016001A1 (enExample)
AU (1) AU1364799A (enExample)
CA (1) CA2349620C (enExample)
DE (1) DE69833134T2 (enExample)
TW (1) TW585772B (enExample)
WO (1) WO1999022744A1 (enExample)
ZA (1) ZA989671B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) * 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
DE10028167B4 (de) * 2000-06-09 2004-02-19 Storch, Rüdiger, Dr. Verwendung von Calciumsalzen zur Entgegenwirkung der Bildung von Oxalatharnsteinen
ES2637020T3 (es) * 2001-04-18 2017-10-10 Genzyme Corporation Uso de polímero de amina para reducir la glucosa sérica
BR0209133A (pt) * 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
EP1923064B1 (en) 2001-04-18 2017-06-28 Genzyme Corporation Use of amine polymer for lowering serum glucose
KR20040018359A (ko) * 2001-04-18 2004-03-03 젠자임 코포레이션 지방족 폴리아민으로 ｘ 증후군을 치료하는 방법
BR0209020A (pt) * 2001-04-18 2004-08-10 Genzyme Corp Composição farmacêutica de polialilamina
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
ATE499943T1 (de) * 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
EP1446481B1 (en) * 2001-10-05 2008-05-21 OxThera, Inc., Materials and methods for reducing oxalate concentrations in fluids
US6600011B2 (en) * 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
ATE389684T1 (de) * 2001-10-09 2008-04-15 Genzyme Corp Verfahren zum reinigen und trocknen von polymerhydrogelen
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
DE112005000725B4 (de) 2004-03-30 2017-12-21 Relypsa, Inc. (n.d.Ges.d. Staates Delaware) Verfahren und Zusammensetzungen zur Behandlung von Ionen-Ungleichgewichten
WO2005110469A2 (en) * 2004-05-07 2005-11-24 Oxthera, Inc. Methods and compositions for reducing oxalate concentrations
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
KR101547925B1 (ko) 2005-09-15 2015-08-27 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
WO2007056405A2 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
AU2005339139A1 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
JP5558002B2 (ja) 2005-12-16 2014-07-23 オクセラ インコーポレイテッド シュウ酸塩低減化のための組成物および方法
JP2009536246A (ja) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
EP2043767B1 (en) 2006-07-14 2020-03-25 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
CA2658338A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
DK2046373T3 (da) * 2006-08-02 2013-05-27 Althea Technologies Inc Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse
WO2008042222A2 (en) 2006-09-29 2008-04-10 Genzyme Corporation Amide dendrimer compositions
JP5535638B2 (ja) * 2006-10-25 2014-07-02 ウィスコンシン アルムニ リサーチ ファンデイション リン酸塩吸収の低減方法
US20100143385A1 (en) * 2006-10-26 2010-06-10 Mark Cook Methods for reducing phosphate absorption
WO2008076242A1 (en) 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
EP2114376A1 (en) * 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
WO2008109095A1 (en) * 2007-03-08 2008-09-12 Genzyme Corporation Sulfone polymer compositions
WO2008113364A2 (en) * 2007-03-20 2008-09-25 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
US20100166696A1 (en) * 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
JP2011506449A (ja) * 2007-12-14 2011-03-03 ジェンザイム コーポレーション コーティング医薬組成物
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
JPWO2010123039A1 (ja) * 2009-04-21 2012-10-25 株式会社医学生物学研究所 生物学的材料の不動化を行うための組成物
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
CA2906501A1 (en) * 2013-03-15 2014-09-25 Genzyme Corporation Sequestrants of advanced glycation end product (age) precursors
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
AU2016244121B2 (en) 2015-04-02 2020-11-05 Orenzymes Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
GB201718803D0 (en) * 2017-11-14 2017-12-27 Phoenix Molecular Pte Ltd Method for isolation of nucleic acids
WO2019236858A1 (en) * 2018-06-06 2019-12-12 The Board Of Trustees Of The University Of Illinois Zwitterionic biocompatible polymers, methods, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198396A (en) * 1974-07-03 1980-04-15 Warren-Teed Laboratories, Inc. Dissolution of gallstones
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
JPS60202869A (ja) * 1984-03-26 1985-10-14 Ajinomoto Co Inc 大環状ポリアミン誘導体及びその用途
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
US5244913A (en) * 1991-11-19 1993-09-14 Baxter International Inc. Compositions and methods for dissolving body calculi
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
ATE361335T1 (de) * 1996-10-23 2007-05-15 Dow Global Technologies Inc Wasserlösliche polymere für die verminderung der absorption von diätetikem phosphat oder oxalat
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate

Also Published As

Publication number Publication date
EP1044008B1 (en) 2006-01-04
EP1645278A2 (en) 2006-04-12
TW585772B (en) 2004-05-01
JP4452402B2 (ja) 2010-04-21
EP1044008A1 (en) 2000-10-18
AU1364799A (en) 1999-05-24
US5985938A (en) 1999-11-16
WO1999022744A1 (en) 1999-05-14
DE69833134D1 (de) 2006-03-30
CA2349620A1 (en) 1999-05-14
JP2001521902A (ja) 2001-11-13
US6177478B1 (en) 2001-01-23
DE69833134T2 (de) 2006-08-10
ZA989671B (en) 1999-04-28
EP1645278A3 (en) 2007-11-14
US6281252B1 (en) 2001-08-28
CA2349620C (en) 2008-04-08

Similar Documents

Publication Publication Date Title
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE69604714D1 (de) Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
DE60025343D1 (de) Pharmazeutische verbindungen
TR199800019T1 (xx) Trombosit topaklanmas�n� �nleyici yeni maddeler.
ES2037753T3 (es) Compuestos heterociclicos y su preparacion y uso.
PA8432901A1 (es) Compuestos de piridilpirrol
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR009129A1 (es) Compuestos derivados de (alfa-aminofosfino)peptidos, procedimientos para preparar los medicamentos constituidos por dichos compuestos, compuestos y usode compuestos intermediarios para preparar dichos compuestos derivados.
ATE88468T1 (de) Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
DE69615555D1 (de) 6-carboxamido-dihydropyran-derivate
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
DK624989D0 (da) Hidtil ukendte forbindelser

Legal Events

Date Code Title Description
FB Suspension of granting procedure